Skip to main content
Premium Trial:

Request an Annual Quote

Ingenium Signs Agreements with Max-Planck and GSF

NEW YORK, Dec. 19 (GenomeWeb News) - Ingenium Pharmaceuticals announced today that it had signed two partnership agreements - one with the Max Planck Institute of Immunology in Freiburg, Germany; and one with the German National Research Center for Environment and Health (GSF).


The Max Planck agreement involves Ingenium's Ingenotyping platform. Ingenium will provide genetic mouse models for target genes to Max Planck using Ingenotyping, a high-speed in vivo target validation tool.


The GSF agreement involves an in-licensing agreement to create the world's largest sperm archive for murine models, according to the company.


Financial terms of the agreements were not disclosed.


The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.